AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
New Fortress Energy
NFE
Cars.com
CARS
Halozyme Therapeutics
HALO
Collegium Pharmaceutical
COLL
US Stock MarketDetailed Quotes
ALGS Aligos Therapeutics
- 10.750
- -0.770-6.68%
Close Mar 21 16:00 ET
- 10.750
- 0.0000.00%
Post 20:01 ET
65.73MMarket Cap-0.51P/E (TTM)
11.885High10.639Low96.63KVolume11.180Open11.520Pre Close1.06MTurnover2.21%Turnover RatioLossP/E (Static)6.11MShares46.80052wk High-2.27P/B47.02MFloat Cap6.76052wk Low--Dividend TTM4.37MShs Float937.748Historical High--Div YieldTTM10.82%Amplitude6.760Historical Low10.936Avg Price1Lot Size
Aligos Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -2.21%-80.74M | 18.78%-18.4M | 1.16%-20.1M | -43.16%-19.49M | -1.60%-22.75M | 0.49%-79M | -35.01%-22.66M | -18.67%-20.34M | 45.61%-13.62M | -9.56%-22.39M |
| Net income from continuing operations | -49.65%-131.21M | -194.53%-82.15M | -6.75%-19.26M | 126.93%5.06M | -51.88%-34.86M | 8.71%-87.68M | -27.44%-27.89M | 3.11%-18.04M | 5.69%-18.79M | 35.55%-22.96M |
| Operating gains losses | 2,010.34%46.13M | 2,764.59%62.13M | --105K | ---30.48M | --14.37M | --2.19M | --2.17M | ---- | ---- | ---- |
| Depreciation and amortization | -14.57%2.62M | -13.42%671K | -2.06%667K | -20.68%610K | -20.14%674K | -16.49%3.07M | -13.60%775K | -24.83%681K | -13.50%769K | -14.14%844K |
| Change In working capital | 47.98%-4.96M | -33.11%-390K | 48.69%-3.18M | 539.35%4.11M | -49.58%-5.49M | -513.72%-9.53M | -133.87%-293K | -118.07%-6.2M | 106.45%643K | -135.31%-3.67M |
| -Change in payables and accrued expense | -2.54%-1.33M | -72.93%1.12M | -12.93%-1.98M | 572.70%4M | -56.91%-4.48M | 82.46%-1.3M | -1.00%4.15M | -264.63%-1.76M | 88.49%-846K | 46.50%-2.85M |
| -Change in other current assets | -90.60%216K | 74.81%-296K | 121.82%170K | -93.63%138K | -90.22%204K | -56.79%2.3M | -105.06%-1.18M | -236.19%-779K | 9.62%2.17M | -37.58%2.09M |
| -Change in other current liabilities | -12.32%-2.68M | -13.88%-714K | -21.57%-699K | -5.17%-631K | -8.90%-636K | -22.23%-2.39M | -1.46%-627K | -52.52%-575K | 34.14%-600K | -1,169.57%-584K |
| -Change in other working capital | 85.78%-1.16M | 80.93%-504K | 78.31%-671K | 896.05%605K | 74.73%-587K | -425.14%-8.14M | -23.62%-2.64M | 24.65%-3.09M | 97.94%-76K | -118.68%-2.32M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -2.21%-80.74M | 18.78%-18.4M | 1.16%-20.1M | -43.16%-19.49M | -1.60%-22.75M | 0.49%-79M | -35.01%-22.66M | -18.67%-20.34M | 45.61%-13.62M | -9.56%-22.39M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -140.64%-18.28M | 285,414.29%19.97M | 115,633.33%10.4M | 59.95%39.99M | -543.37%-88.64M | 271.08%44.98M | -100.06%-7K | -100.03%-9K | 350.64%25M | 133.10%19.99M |
| Net PPE purchase and sale | -584.21%-130K | -300.00%-28K | -36.84%-26K | -150.00%-7K | -885.71%-69K | 97.99%-19K | 92.31%-7K | -533.33%-19K | 104.19%14K | 98.64%-7K |
| Net investment purchase and sale | -140.33%-18.15M | --20M | 104,140.00%10.42M | 60.06%40M | -542.87%-88.57M | 277.51%45M | --0 | -99.97%10K | 359.18%24.99M | 133.40%20M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -140.64%-18.28M | 285,414.29%19.97M | 115,633.33%10.4M | 59.95%39.99M | -543.37%-88.64M | 271.08%44.98M | -100.06%-7K | -100.03%-9K | 350.64%25M | 133.10%19.99M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -99.60%355K | -99.89%97K | 80.95%-4K | -32.13%281K | -1,800.00%-19K | 53,758.54%88.33M | 72,574.38%87.94M | -10.53%-21K | 398.80%414K | 95.24%-1K |
| Net issuance payments of debt | 13.54%-83K | -975.00%-43K | 76.19%-5K | 65.96%-16K | 20.83%-19K | -57.38%-96K | -114.81%-4K | 25.00%-21K | -62.07%-47K | 22.58%-24K |
| Net common stock issuance | --0 | ---- | ---- | ---- | ---- | --17.44M | ---- | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | -99.38%438K | -99.80%140K | --1K | -35.57%297K | --0 | 31,447.11%70.98M | 74,896.81%70.5M | --0 | 311.61%461K | 130.00%23K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -99.60%355K | -99.89%97K | 80.95%-4K | -32.13%281K | -1,800.00%-19K | 53,758.54%88.33M | 72,574.38%87.94M | -10.53%-21K | 398.80%414K | 95.24%-1K |
| Net cash flow | ||||||||||
| Beginning cash position | 66.67%135.77M | -49.73%35.44M | -50.32%45.15M | -69.18%24.37M | 66.67%135.77M | -56.43%81.46M | -18.51%70.5M | 27.64%90.87M | -25.49%79.07M | -56.43%81.46M |
| Current changes in cash | -281.67%-98.67M | -97.45%1.67M | 52.34%-9.71M | 76.08%20.78M | -4,551.65%-111.41M | 151.47%54.31M | 1,390.45%65.27M | -232.88%-20.37M | 133.79%11.8M | 97.04%-2.4M |
| End cash Position | -72.67%37.11M | -72.67%37.11M | -49.73%35.44M | -50.32%45.15M | -69.18%24.37M | 66.67%135.77M | 66.67%135.77M | -18.51%70.5M | 27.64%90.87M | -25.49%79.07M |
| Free cash flow | -2.35%-80.87M | 18.68%-18.43M | 1.09%-20.13M | -43.29%-19.5M | -1.88%-22.82M | 1.64%-79.02M | -34.32%-22.67M | -18.72%-20.35M | 46.36%-13.61M | -6.90%-22.39M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |